Patient dosing initiated for Phase 2b study of PUR1900 for ABPA
Phase 1 study of PUR3100 for migraine achieves positive topline results
$30.8 million in cash and cash equivalents at the end of Q1 2023 providing projected cash runway into Q4 2024
Read more at prnewswire.com